Erschienen in:
23.11.2020 | Breast Oncology
Axillary Downstaging in ER+/HER2− Breast Cancer: OncotypeDX As a Tool to Guide Neoadjuvant Approach
verfasst von:
Olga Kantor, MD, MS, Suzanne B. Coopey, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 3/2021
Einloggen, um Zugang zu erhalten
Excerpt
The rates of pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in both the breast and axilla vary greatly by tumor subtype, with estrogen receptor-positive, HER2-negative (ER
+/HER
2−) tumors having notoriously low response rates. Subtype analysis of the American College of Surgeons Oncology Group/Alliance Z1071 trial of patients undergoing contemporary chemotherapy with biopsy-proven clinically node-positive breast cancer found overall pCR rates of 11% in ER
+/HER
2− cancers, with axillary pCR rates of 21%.
1 While a neoadjuvant approach is key to axillary downstaging in more responsive tumor subtypes, most patients with clinically node-positive ER
+/HER
2− breast cancer will still require axillary dissection. Because axillary dissection carries inherent risks of arm lymphedema and shoulder dysfunction that can negatively impact quality of life, it is important to consider innovative strategies to optimize axillary downstaging for patients with ER
+/HER
2− breast cancer. …
